Smith & Nephew SNATS Inc Stock News

Smith & Nephew PLC (LSE:SN)'s underperformance is set to change, according to Goldman Sachs (NYSE:GS). The investment bank has initiated coverage of the medical technology outfit with a buy rating and

For weeks, I have pounded the table about the historic opportunity in REITs. The fundamentals were clear that now was the best time in 14 years to buy REITs. Last week, stocks ripped 6% higher, and RE

Smith & Nephew plc (NYSE:SNN ) Q3 2023 Earnings Conference Call November 2, 2023 4:30 AM ET Company Participants Deepak Nath - Chief Executive Officer Anne-Francoise Nesmes - Chief Financial Officer C

JPMorgan has upgraded the firm to overweight from neutral pointing out shares have de-rated to 10-year lows in recent weeks. This reflected concerns on a margin guidance downgrade post-H1 soft margins

Shares in Smith & Nephew PLC (LSE:SN) surged by 4.2% as the company projected sales growth to hit the upper end of its guidance following a robust third quarter, despite a slight tempering of margin g

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest

Smith & Nephew (SNN) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revi

Smith & Nephew plc (NYSE:SNN ) Q2 2023 Earnings Conference Call August 3, 2023 3:30 AM ET Company Participants Deepak Nath - Chief Executive Officer Anne-Francoise Nesmes - Chief Financial Officer Con

Smith & Nephew PLC (LSE:SN) reported improved revenue, profit and margin in the first half making progress towards achieving sustainable higher growth under its 12-point plan. In the six months to Jul

Smith & Nephew plc is a long-standing company in the medical device sector, focusing on developing and manufacturing internationally. The company has recently received FDA clearance for its AETOS Shou

After a pandemic pause, hip and knee replacements are back. Long-postponed surgeries are being rescheduled, which is bad for business at insurance companies like UnitedHealth Group Inc. NYSE: UNH, but

Smith & Nephew PLC (LSE:SN) held full-year guidance as it reported strong growth in its Sports Medicine and Advanced Wound Management businesses had underpinned an improvement in first quarter revenue

RBC Capital said expects Smith & Nephew PLC (LSE:SN) to post revenue growth of 3.9% in the first quarter, as the company benefits from positive trends in US elective procedures while facing headwinds

You don't see financial TV channels dedicated to minute-by-minute coverage of dividend yield or increases, but for investors in companies like Sanofi (NASDAQ: SNY), AstraZeneca plc (NASDAQ: AZN), and